NTRB - התחייבויות לטווח ארוך של החברה nutriband.com

Nutriband Inc. develops transdermal drug delivery systems, leveraging partnerships with laboratories to accelerate asset licensing. Aversa technology makes severe pain therapy safe by preventing the misuse of medications. This price chart demonstrates the asset's dynamics, where the long-term debt metric stands at 0.00. In the future, the binary risks of new product development will be mitigated by the possession of unique patents for physical protection.

Nutriband Inc. minimizes capital expenditures by lacking its own production facilities, shifting the focus of financial control toward the management of external financing. By analyzing the firm's long-term debt via GURU.Markets, an investor assesses the volume of obligations with maturities exceeding one year, where a decrease in debt signals deleveraging, while an increase indicates the procurement of liquidity to scale the business.